Physician profile
Lwin Win
NPI 1912119595
$687.24
in general payments reported to CMS, 2019-2025
15 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.33 · 2020: $60.95 · 2021: $19.16 · 2022: $269 · 2023: $90.84 · 2024: $120 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148.72 | 2020-2025 | Wegovy |
| Abbott Laboratories | $97.94 | 2022-2025 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $67.74 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $65.31 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $57.50 | 2023-2025 | Ubrelvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.18 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $37.26 | 2019-2022 | |
| Amgen INC. | $31.48 | 2022 | |
| Pfizer INC. | $26.68 | 2019-2024 | |
| Esperion Therapeutics, INC. | $26.28 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2022 | |
| Grifols USA, LLC | $19.51 | 2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $19.16 | 2021 | |
| Axsome Therapeutics, INC. | $13.51 | 2025 | Auvelity |
| Scilex Pharmaceuticals INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lwin Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.